Company news

Immunovant, Inc. news in 2023

Immunovant, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 19, 2023

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 19, 2023

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 27, 2023

Immunovant to Present at Upcoming Investor Conferences

November 12, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

November 8, 2023

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 1, 2023

Immunovant Announces Pricing of $450 Million Common Stock Financing

September 26, 2023

Immunovant Announces Proposed Offering of $300 Million of Common Stock

September 25, 2023

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 25, 2023

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

September 24, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

August 9, 2023

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

May 21, 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

February 2, 2023

Decks in 2023